TAYSHA GENE THERAPIES INC

NASDAQ: TSHA (Taysha Gene Therapies, Inc.)

Last update: 22 hours ago

4.10

-0.11 (-2.61%)

Previous Close 4.21
Volume 2,474,566
Price / Sales 280.23
Price / Book 3.74
52 Weeks Range
3.46 (-15%) — 7.30 (78%)
Operating Margin (TTM) -930.54%
Diluted EPS (TTM) -0.340
Quarterly Revenue Growth (YOY) -32.50%
Total Debt/Equity (MRQ) 111.93%
Current Ratio (MRQ) 5.35
Operating Cash Flow (TTM) -83.45 M
Levered Free Cash Flow (TTM) -52.28 M
Return on Assets (TTM) -35.91%
Return on Equity (TTM) -159.34%

AIStockmoo Score

-0.5
Value 30% -1.4
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 30% -2.4
From our AI technical analysis of the chart. info NA
No clear trend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% 3.2
Insider Activity info NA
Institutions net +10.38% of shares in their latest 13F filings: 137 holders increased, 74 decreased (quarter to 30 Sep 2026). info
Short interest +14.3% from 31 Aug to 30 Oct 2026, 14.8 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Not in score
Price is low against its 52-week average. Down over 5 years. info
Short-term momentum rising. info
Price is near support. Levels trending down. info
Final Score -0.49

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Taysha Gene Therapies, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TSHA - - - 3.74
VRNA 9 B - - 33.01
OPT 583 M - - 4.31
VRCA - - - 15.60
ABEO - - - 1.04
VKTX - - - 6.33

Select this tab to load the latest available analysis.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 12.11%
% Held by Institutions 67.23%

Ownership

Name Date Shares Held
Polar Capital Holdings Plc 30 Jun 2026 5,117,133

No data within this time range.

Institutions

Institutional ownership: 97.20%

Positions Holders Shares
Increased 137 37,295,049
Decreased 74 15,115,926
New 43 16,801,077
Sold out 22 5,137,834

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 53,478,497 14.8
15 Oct 2026 51,249,292 11.6
30 Sep 2026 55,020,663 11.2
15 Sep 2026 51,405,384 18.8
31 Aug 2026 46,800,424 19.4
14 Aug 2026 46,738,149 17.4

FINRA short interest via Nasdaq, reported twice a month.

0 Positive 0 Negative 5 Neutral
Date Type Details
13 Nov 2026 Yahoo Finance Taysha (TSHA) Q3 2026 Earnings Call Transcript
Management says 33 patients dosed so far with no severe treatment-related events.
12 Nov 2026 Yahoo Finance Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company’s third-quarter earnings call. The comp…
12 Nov 2026 Yahoo Finance Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across…
06 Nov 2026 Yahoo Finance Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
05 Nov 2026 Yahoo Finance Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
30 Oct 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
Taysha Gene Therapies has seen sharp swings in its share price over recent years, and that volatility puts a spotlight on a basic question for holders: Is the market value you see on screen today in line with what its balance sheet and book value can reasonably support? Over the past 3 years the…
18 Oct 2026 Yahoo Finance Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-related serious adverse events were observed. These findings support the therapy's…
09 Oct 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind of move is backed up by the value on its balance sheet. With the share price at US$4.43 at the last close, the live question is how comfortably that level sits against the…
09 Oct 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Taysha Gene Therapies (TSHA) has drawn fresh attention after a period of pressure on the share price, with the stock roughly flat over the past day but lower over the past month and the past three months. Short term momentum for Taysha Gene Therapies has clearly cooled, with the 7 day share price…
01 Oct 2026 Yahoo Finance Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
07 Sep 2026 Yahoo Finance These 3 Risky Stocks Could Be Sitting on 100% Upside
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.
18 Aug 2026 Yahoo Finance Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate.
Show more

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria